www.navidea.com/
www.navidea.com/development-programs/
www.navidea.com/development-programs/
Top-News
Navidea Biopharmaceuticals, Inc. (NAVB)
Beiträge: 62
Zugriffe: 14.388 / Heute: 1
Zugriffe: 14.388 / Heute: 1
|
| 36 Beiträge ausgeblendet. |
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +37,75%
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +37,68%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +37,07%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +36,39%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +31,25%
www.nasdaq.com/de/symbol/navb/real-time
( und das lustige ist , ich höre mir gerade das Lied "Schlechte Laune" von WIZO an -----LOL )
mstx - gerade dip , sollten paar %% jetzt drin sein www.nasdaq.com/de/symbol/mstx/real-time
Bin ungefähr so rein wie du, bei 0.56$.
Ich wette, die läuft Morgen noch über den Dollar, nach dem Aktionärs-Call.
80 Mille Cash + Verkaufbeteidigung bis max. 310 Millionen.
Die war so abgesackt, weil se ein Gerichtsverfahren verloren hatten, wodurch sie ihrem alten Investor ca. 55 Millionen zahlen sollten, in den nächsten 21 Tagen und noch kein neuer feststand.
Nu können sie sich komplett Schuldenfrei machen und haben Kohle für ihre anderen Pipelinesachen!
War letzte Woche schon drinne, hab aber zu 0,33!!!! wieder verkauft, ich Depp!
Ich wette, die läuft Morgen noch über den Dollar, nach dem Aktionärs-Call.
80 Mille Cash + Verkaufbeteidigung bis max. 310 Millionen.
Die war so abgesackt, weil se ein Gerichtsverfahren verloren hatten, wodurch sie ihrem alten Investor ca. 55 Millionen zahlen sollten, in den nächsten 21 Tagen und noch kein neuer feststand.
Nu können sie sich komplett Schuldenfrei machen und haben Kohle für ihre anderen Pipelinesachen!
War letzte Woche schon drinne, hab aber zu 0,33!!!! wieder verkauft, ich Depp!
Momentan wieder günstiger Einstieg.
aktuell zu heiß gelaufen, auch wenn aktuell wieder 25 Prozent im Plus.
The most important near term implication of this deal is that Navidea (subject to closing) can now pay off the $50 million debt it owes to CRG, in full, and free itself of the drag that the litigation has been putting on the company and its operations. This is not to be underestimated. The company’s CEO left earlier this year, primarily based on the impact of the litigation (whatever the media said) and reports of low morale, disgruntled staff and the reluctance of certain potential partners to strike deals with the company have hampered growth. The lifting of this situation is hugely important going forward.
The second implication is that Navidea now no longer has a revenue source. That’s not great, but according to a conference call held by management to discuss the deal, the company believes the potential future revenues from the development of its pipeline, specifically a rheumatoid arthritis treatment, outweigh the ROI on a marketing push for its Lymphoseek product.
This move can be interpreted as follows. The company is monetizing an asset to shore up its capital structure, and putting any remaining proceeds into its pipeline. We see this as a smart move. Why? Because any future growth potential was severely stunted by the company’s pre-agreement situation (of course, it’s very much still in this situation, but we are assuming the Cardinal Health deal will close out successfully).
Navidea is now an early stage junior biotech with a couple of promising candidates in its pipeline, no debt and a partnership that is set to bring in just shy of $7 million annually at the bottom end for at least three years. It should have cash on hand at close (and after paying off the debt and litigation costs) of between $25-30 million, and intends to counter CRG in the hope it can recoup some of its capital going forward.
That’s a pretty healthy position, and a complete turnaround for a company that, just last month, looked like a candidate for insolvency.
streetregister.com/2016/09/09/...pivots-poised-for-turnaround/
The second implication is that Navidea now no longer has a revenue source. That’s not great, but according to a conference call held by management to discuss the deal, the company believes the potential future revenues from the development of its pipeline, specifically a rheumatoid arthritis treatment, outweigh the ROI on a marketing push for its Lymphoseek product.
This move can be interpreted as follows. The company is monetizing an asset to shore up its capital structure, and putting any remaining proceeds into its pipeline. We see this as a smart move. Why? Because any future growth potential was severely stunted by the company’s pre-agreement situation (of course, it’s very much still in this situation, but we are assuming the Cardinal Health deal will close out successfully).
Navidea is now an early stage junior biotech with a couple of promising candidates in its pipeline, no debt and a partnership that is set to bring in just shy of $7 million annually at the bottom end for at least three years. It should have cash on hand at close (and after paying off the debt and litigation costs) of between $25-30 million, and intends to counter CRG in the hope it can recoup some of its capital going forward.
That’s a pretty healthy position, and a complete turnaround for a company that, just last month, looked like a candidate for insolvency.
streetregister.com/2016/09/09/...pivots-poised-for-turnaround/
www.nasdaq.com/de/symbol/navb/real-time
www.nasdaq.com/de/symbol/navb/real-time
www.nasdaq.com/de/symbol/navb/premarket
investorshub.advfn.com/boards/...msg.aspx?message_id=125316819
www.nasdaq.com/de/symbol/navb/premarket
|
Neueste Beiträge aus dem Navidea Biopharmaceuticals Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 61 | Navidea Biopharmaceuticals, Inc. (NAVB) | Heron | wennichdaswueste | 24.04.21 23:52 |
